Multitumor Case Series of Germline <i>BRCA1</i>, <i>BRCA2</i> and <i>CHEK2</i>-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors

In recent years, immune checkpoint inhibitors (ICPI) have become widely used for multiple solid malignancies. Reliable predictive biomarkers for selection of patients who would benefit most are lacking. Several tumor types with somatic or germline alterations in genes involved in the DNA damage resp...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Lisa Kinget, Oliver Bechter, Kevin Punie, Philip R. Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, Yannick Van Herck, Maarten Albersen, Marcella Baldewijns, Patrick Schöffski, Benoit Beuselinck
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2021-08-01
Reeks:	Current Oncology
Onderwerpen:	DNA damage response immune checkpoint inhibitors <i>BRCA1</i> <i>BRCA2</i> <i>CHEK2</i>
Online toegang:	https://www.mdpi.com/1718-7729/28/5/280
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!